Selected article for: "capsid protein and Nitric oxide"
Author: Vijayan, Veena; Mohapatra, Adityanarayan; Uthaman, Saji; Park, In-Kyu
Title: Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials
  • Document date: 2019_10_14
    • ID: 1d3xthbh_60
    Snippet: Foot-and-mouth disease (FMD) is a highly infectious disease caused by FMD viruses found in cloven-hoofed animals; it is transmissible from animal to human [10, 143] . FMDV vaccination is the traditional approach, which is time-consuming and expensive. It is less useful to induce sufficient mucosal immunity against the FMDV. NPs are a well-known drug carrier for antigens and adjuvants and can produce strong resistance. Teng et al. [144] developed .....
    Document: Foot-and-mouth disease (FMD) is a highly infectious disease caused by FMD viruses found in cloven-hoofed animals; it is transmissible from animal to human [10, 143] . FMDV vaccination is the traditional approach, which is time-consuming and expensive. It is less useful to induce sufficient mucosal immunity against the FMDV. NPs are a well-known drug carrier for antigens and adjuvants and can produce strong resistance. Teng et al. [144] developed an FMD vaccine by using gold nanostars (AuSNs) and FMD VLP (FMD VLPs-AuSNs) complexes. FMD VLPs-AuSNs nanovaccines (shown in Figure 9 ) augmented a robust immune response against FMDV. This biomimetic vaccine manifested a high cellular uptake, due to VLP modification. The macrophage activation with FMD VLPs-AuSNs was relatively higher than VLPs, because AuNPs and the nitric oxide production induced a robust immune activation against the FMDV. Another biomimetic nanovaccine was formulated by using synthetic peptide derived from the FMDV and gold NP (AuNP) [143] . The synthetic peptide of the capsid protein (VP1) of the FMDV had a strong immune activation in guinea pigs with 40% higher efficacy, compared to that for the FMD vaccine.

    Search related documents:
    Co phrase search for related documents
    • macrophage activation and mucosal immunity: 1, 2
    • macrophage activation and nitric oxide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • macrophage activation and nitric oxide production: 1, 2, 3, 4, 5
    • macrophage activation and robust FMDV immune activation: 1, 2
    • macrophage activation and robust FMDV immune response: 1, 2
    • macrophage activation and strong resistance: 1, 2
    • macrophage activation and strong resistance produce: 1, 2
    • macrophage activation and sufficient FMDV mucosal immunity: 1, 2
    • macrophage activation and sufficient FMDV mucosal immunity induce: 1, 2
    • macrophage activation and synthetic peptide: 1, 2
    • macrophage activation and traditional approach: 1, 2
    • macrophage activation and VLP modification: 1, 2
    • macrophage activation and VP1 capsid protein: 1, 2
    • mouth Foot disease and sufficient FMDV mucosal immunity: 1, 2
    • mouth Foot disease and sufficient FMDV mucosal immunity induce: 1, 2
    • mouth Foot disease and synthetic peptide: 1, 2, 3, 4
    • mouth Foot disease and traditional approach: 1, 2
    • mouth Foot disease and VLP modification: 1, 2
    • mouth Foot disease and VP1 capsid protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11